Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models

Clinical Cancer Research

Volumn 21, Issue 23, 2015, Pages 5338-5348

  Liu, Yan ^a,b,c,e   Hawkins, Oriana E ^a,b,e   Vilgelm, Anna E ^a,b   Pawlikowski, Jeffrey S ^a,b   Ecsedy, Jeffrey A ^d   Sosman, Jeffrey A ^c   Kelley, Mark C ^b   Richmond, Ann ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; ANTINEOPLASTIC AGENT; AURORA KINASE; AURORA KINASE INHIBITOR; B RAF KINASE; BARASERTIB; BETA GALACTOSIDASE 1; CASPASE; CXCL1 CHEMOKINE; CYCLIN A2; DEATH RECEPTOR 5; DEATH RECEPTOR 5 AGONIST; DEATH RECEPTOR 5 AGONIST ANTIBODY; DELETED IN ESOPHAGEAL CANCER 1 PROTEIN; DROZITUMAB; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 8; ONCOPROTEIN; PIFITHRIN ALPHA; PROTEIN NRAS; PROTEIN P16; PROTEIN P21; PROTEIN P53; RECOMBINANT HUMAN APO2L TRAIL DECOY RECEPTOR AGONIST; RECOMBINANT HUMAN APO2L TRAIL DECOY RECEPTOR OSTEOPROTEGERIN AGONIST; SURVIVIN; TOZASERTIB; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; AZEPINE DERIVATIVE; DEATH RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DEPOLARIZATION; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MITOCHONDRION; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL AGING; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; PATHOLOGY; PRECLINICAL STUDY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; AURORA KINASES; AZEPINES; CASPASES; CELL AGING; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MELANOMA; MICE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 10C; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84954181535     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0293     Document Type: Article

References (52)

1. Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, et al. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-kappaB impairs this drug-induced senescence. EMBO Mol Med 2013;5:149-66.
2. Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, et al. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007;128: 295-308.
3. Lin HK, Chen Z, WangG, Nardella C, Lee SW, Chan CH, et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010;464:374-9.
4. Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010;120:681-93.
5. Liu W, Sharpless NE. Senescence-escape in melanoma. Pigment Cell Melanoma Res 2012;25:408-9.
6. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62:1876-83.
7. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-46.
8. Ewald JA,Desotelle JA,Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010;102:1536-46.
9. Muller I, Niethammer D, Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity. Int J Mol Med 1998; 1:491-4.
10. Hato SV, Khong A, deVries IJ, Lesterhuis WJ. Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res 2014;20:2831-7.
11. Hilton JF, Shapiro GI. Aurora kinase inhibition as an anticancer strategy. J Clin Oncol 2014;32:57-9.
12. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, et al. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 2012;18: 4775-84.
13. Friedberg JW,MahadevanD,Cebula E, PerskyD, Lossos I, Agarwal AB, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B-and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014;32:44-50.
14. Matulonis UA, Sharma S, Ghamande S, Gordon MS, DelPrete SA, Ray-Coquard I, et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or-refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecologic oncology 2012;127:63-9.
15. Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, et al. Mdm2and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 2015;75:181-93.
16. Venkatakrishnan K, Friberg LE, Ouellet D,Mettetal JT, Stein A, Troconiz IF, et al. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: Challenges and opportunities. J Clin Oncol 2015;97:37-54.
17. Palani S, Patel M, Huck J, Zhang M, Balani SK, Yang J, et al. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Chemother Pharmacol 2013;72:1255-64.
18. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011;479:547-51.
19. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60.
20. Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 2013;210:2057-69.
21. Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, et al. Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res 2011;71:675-85.
22. Gonzalvez F, LawrenceD, Yang B, Yee S, Pitti R, Marsters S, et al. TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol Cell 2012;48:888-99.
23. Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL, et al. Smallmolecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol 2013;9:84-9.
24. Tabbert A, Kappes F, Knippers R, Kellermann J, Lottspeich F, Ferrando-May E. Hypophosphorylation of the architectural chromatin protein DEK in death-receptor-induced apoptosis revealed by the isotope coded protein label proteomic platform. Proteomics 2006;6:5758-72.
25. Tchkonia T, Zhu Y, vanDeursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J Clin Invest 2013;123:966-72.
26. Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010; 29:273-83.
27. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging. Proc Natl Acad Sci U S A 2001;98:12072-7.
28. Bhatia B, Multani AS, Patrawala L, Chen X, Calhoun-Davis T, Zhou J, et al. Evidence that senescent human prostate epithelial cells enhance tumorigenicity: Cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT. Int J Cancer 2008;122:1483-95.
29. Pribluda A, Elyada E, Wiener Z, Hamza H, Goldstein RE, Biton M, et al. A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer cell 2013;24:242-56.
30. Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 2007;67:3117-26.
31. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006;8:877-84.
32. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008;133:1006-18.
33. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008;133:1019-31.
34. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011; 192:547-56.
35. Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, et al. Non-cell-autonomous tumor suppression by p53. Cell 2013;153:449-60.
36. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134:657-67.
37. Shao L, Wang Y, Chang J, Luo Y,Meng A, Zhou D. Hematopoietic stem cell senescence and cancer therapy-induced long-term bone marrow injury. Transl Cancer Res 2013;2:397-411.
38. Montes CL, Chapoval AI, Nelson J, Orhue V, Zhang X, Schulze DH, et al. Tumor-induced senescent T cells with suppressor function: A potential form of tumor immune evasion. Cancer Res 2008;68:870-9.
39. Gastman BR, Yin XM, Johnson DE, Wieckowski E, Wang GQ, Watkins SC, et al. Tumor-induced apoptosis of T cells: Amplification by a mitochondrial cascade. Cancer Res 2000;60:6811-7.
40. Ye J, Ma C, Hsueh EC, Dou J, Mo W, Liu S, et al. TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. EMBO Mol Med 2014;6:1294-311.
41. Almasan A, Ashkenazi A. Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. CytokineGrowth Factor Rev 2003;14:337-48.
42. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-30.
43. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
44. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
45. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008;15:751-61.
46. Estes JM, Oliver PG, Straughn JM Jr, Zhou T, Wang W, Grizzle WE, et al. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 2007;105:291-8.
47. Derosier LC, Vickers SM, Zinn KR, Huang Z, Wang W, Grizzle WE, et al. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther 2007;6:3198-207.
48. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010;16:1256-63.
49. Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008;6:1861-71.
50. Lin Y,Devin A, Rodriguez Y, Liu ZG. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 1999;13:2514-26.
51. Ding L, Yuan C, Wei F,Wang G, Zhang J, Bellail AC, et al. Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest; 2011;29:511-20.
52. Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, et al. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res 2010;16:2591-604.